Figures & data
Figure 1. Experimental groups and isolated heart perfusion protocols. All groups were TTC stained for infarct size determination. Tissue analysis for characterization of HPB were performed on selected groups.
Figure 3. a: Infarct size in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. b: O-GlcNAc levels in in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. c: O-GlcNAc transferase activity in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. d: O-GlcNAc transferase levels in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. e: O-GlcNAcase activity in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. f: O-GlcNAcase levels in control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan treated hearts. All data presented are mean ± SEM.
Figure 4. Left ventricular developed pressure (LVDP) during reperfusion in a: control and IPC hearts, b: control + 80 μM azaserine and IPC + 80 M azaserine treated hearts, and c: control + 5 mM alloxan and IPC + 5 mM alloxan. All data presented are mean ± SEM. **p < 0.05 compared to control.
Figure 2. Representative O-GlcNAc (CTD 110.6) and actin immunoblots from control, IPC, control + 80 μM azaserine, IPC + 80 μM azaserine, control + 5 mM alloxan, and IPC + 5 mM alloxan.
